Cuatrecasas advises Columbus Partners and Mérieux Equity Partners on their investment in Ona Therapeutics, which is developing new cancer treatments

by Cuatrecasas

Cuatrecasas advised Columbus Venture Partners and Mérieux Equity Partners on their participation as co-lead investors in Ona Therapeutics Series B financing. Ona Therapeutics is a pioneering biopharm...

Read more

Ona Therapeutics Raises $86.6 Million Series B co-led by Columbus Venture Parrners and Mérieux Equity Partners to Advance First-in-Class ADCs into Clinical Development

by Columbus Venture Partners

The round was co-led by new investors Columbus Venture Partners and Mérieux Equity Partners, with participation from additional investors COFIDES and Korys, alongside all existing investors Alta Life...

Read more

SOKAI secures €64.5 million in funding to develop its life sciences hub in San Sebastián

by Buenavista Equity Partners

The total planned investment for the development is around €80 million, with the asset expected to be partially operational at the beginning of 2027. This financing represents one of the most signif...

Read more

Columbus Venture Partners and Concentric co-lead a funding round in Visium to accelerate AI adoption in the pharmaceutical and biotechnology industries

by Columbus Venture Partners

Visium has grown to a team of 100 AI experts across Europe and has delivered more than 250 AI and data solutions for global leaders in life sciences, specialty chemicals and other regulated industries...

Read more

Columbus Venture Partners and ABE Capital Partners acquire a majority stake in Sermes CRO

by Columbus Venture Partners

Sermes CRO is a Spanish contract research organization (CRO) with 29 years of experience, dedicated to optimizing clinical research processes for pharmaceutical and biotechnology companies, as well as...

Read more

Buenavista Equity Partners and Columbus Venture Partners agree to sell Syngoi Technologies to Artis BioSolutions

by Buenavista Equity Partners

Syngoi is a Contract Development and Manufacturing Organisation (CDMO) specialising in synthetic DNA for advanced therapies, a critical component for therapeutic applications such as mRNA vaccines, ge...

Read more

Columbus Venture Partners successfully completes the sale of Syngoi Technologies to U.S. based Artis BioSolutions

by Columbus Venture Partners

Syngoi Technologies has developed in recent years its own enzymatic synthetic DNA platform, designed to address one of the key structural challenges in the gene and cell therapy industry: the efficien...

Read more

Columbus Venture Partners participates in a $12.7M seed round of Accipiter Biosciences

by Columbus Venture Partners

The company has developed an advanced computational platform, combined with high-throughput experimentation, that uses proprietary methods to design multifunctional de novo proteins. These proteins, b...

Read more

CDTI invests in Integra Therapeutics, together with Invivo, Columbus, and AdBio Partners

by CDTI Innovación

Innvierte SICC of CDTI Innovación invests in Integra Therapeutics, together with three co-investors, to develop a gene-editing platform for the treatment of oncological, autoimmune, and genetic disea...

Read more

ARTHEx Biotech Upsizes Series B Financing Round to $87 millones

by Columbus Venture Partners

The Series B extension financing was led by Bpifrance and joined by all existing shareholders, including AdBio Partners, CDTI Innovación, Columbus Venture Partners, European Innovation Council (EIC),...

Read more

Buenavista leads a €15 million funding round in Highlight Therapeutics

by Buenavista Equity Partners

Buenavista Equity Partners, through its specialized fund BV Healthcare Growth Innvierte I (BHG I) created in collaboration with Columbus Venture Partners, has announced its entry into the shareholding...

Read more

Integra Therapeutics closes a €10.7 million funding round, with participation from Columbus, EIC Fund, CDTI, Invivo, Takeda, and AdBio

by CDTI Innovación

The funds will be used to incorporate new advances into the FiCAT gene writing platform, validate various next generation CAR-T therapies in the preclinical phase and expand the FiCAT cell engineering...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

Mediterrania Capital Partners posts 22% ...

by Mediterrania Capital Partners

Across all funds, MCP’s 13 portfolio companies delivered revenues of...

Photos Stream